Pasithea Therapeutics (KTTA) Net Margin (2022)
Pasithea Therapeutics recorded quarterly Net Margin of 442.14% in Q4 2022, down 144.64% quarter-over-quarter from 180.73% in Q3 2022.
Pasithea Therapeutics' Net Margin history runs 1 years deep, the most recent figure standing at 442.14% for Q4 2022.
- In Q4 2022, Net Margin changed N/A year-over-year to 442.14%; the TTM figure through Dec 2022 stood at 463.16% (changed N/A YoY), while the FY2022 annual figure was 453.92%, up 1397658.0% from the prior year.
- Net Margin came in at 442.14% for Q4 2022 at Pasithea Therapeutics, down from 180.73% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 180.73% in Q3 2022 to a low of 3449.93% in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -442.14% |
| Sep 30, 2022 | -180.73% |
| Jun 30, 2022 | -3,449.93% |
| Mar 31, 2022 | -2,384.38% |